Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Revvity, Inc. RVTY announced the launch of its new IDS i20 analytical random-access platform from EUROIMMUN. Per management, ...

Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...

At the EuroPCR 2025, Edwards Lifesciences EW has announced new economic and clinical evidence on severe aortic stenosis (AS). The results of a new real-world study, comprising more than 24,000 ...

Point-of-care medication dispensing offers a return to a more straightforward approach, common to physician practices ...

Hims shares have roughly doubled since the start of the year, despite the FDA’s announcement last week that Novo Nordisk’s drug semaglutide is no longer in shortage in the U.S.

Here's the list of options activity happening in today's session: These itemized elaborations have been created using the accompanying table. • For CVS CVS +0.23% Get Free Report , we notice a put ...

Discover the risks threatening dividend stocks, from high interest rates to the AI revolution. Click for my look at several ...

As the United States market grapples with renewed trade tensions and fluctuating indices, investors are keenly observing the impact on economic growth and corporate profits. In such a volatile ...

Bristol Myers Squibb is storming ASCO 2025 with data from over 80 studies covering 20+ cancer types, showcasing its oncology ...